SC to hear plea against Ranbaxy on Jun 24

Published: 17th June 2013 04:40 PM  |   Last Updated: 17th June 2013 04:41 PM   |  A+A-


Supreme Court will hear on June 24 a petition seeking probe against Ranbaxy Laboratories Ltd for allegedly manufacturing and selling adulterated medicines.

A bench of justices A K Patnaik and Ranjan Gogoi on Monday agreed to hear the PIL after the petitioner, advocate M L Sharma pleaded for an urgent hearing in the case.

The case was earlier heard by a different vacation bench which had on June 10 asked Sharma to substantiate his "unfounded allegations" that the Indian pharma major was allegedly manufacturing and selling adulterated medicines. He, thereafter, filed an additional affidavit in the case.

The PIL alleged that the company has been fined USD 500 million by the US Food and Drug Administration (USFDA) for making and selling "adulterated" drugs. It also sought sealing of all its manufacturing units here, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.

The petitioner alleged that despite Ranbaxy pleading guilty to supplying adulterated drugs in the US and it being fined such a huge amount, the Centre has not taken any action to prohibit or ban the drugs made by the company.

He also sought action against Indian drug regulator, Central Drug Standards Control Organisation (CDSCO), for permitting Ranbaxy to sell drugs in India, especially in the wake of the results of the USFDA probe against the company.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp